Grace Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Grace Therapeutics is a pharmaceutical company developing therapies for underserved neurological and other rare conditions, including an intrathecal drug candidate for aneurysmal subarachnoid hemorrhage. It is headquartered in Princeton, New Jersey.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Opaleye Management Inc.10% Owner | Buy | $5K | 3,087at $1.77 | Nov 5, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $9K | 5,027at $1.80 | Nov 4, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $18K | 10,328at $1.79 | Nov 3, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $117K | 66,411at $1.77 | Oct 26, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $41K | 21,390at $1.93 | Oct 22, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $8K | 4,256at $1.88 | Oct 19, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $22K | 11,233at $1.93 | Oct 14, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $46K | 23,485at $1.95 | Oct 15, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $69K | 36,347at $1.89 | Oct 16, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $4K | 2,077at $2.02 | Oct 8, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $15K | 7,215at $2.02 | Oct 12, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $11K | 5,340at $2.04 | Oct 9, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $3K | 1,694at $2.06 | Oct 5, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $41K | 20,000at $2.07 | Oct 2, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $79K | 38,796at $2.04 | Oct 1, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $11K | 5,318at $2.10 | Sep 23, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $21K | 9,771at $2.10 | Sep 21, 2026 |
| Opaleye Management Inc.10% Owner | Buy | $24K | 11,608at $2.09 | Aug 14, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable GRCE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.